NCT06940739View on ClinicalTrials.gov

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 11, 2025

Primary Completion Date

June 30, 2032

Study Completion Date

July 31, 2032

Conditions
Unresectable MelanomaMetastatic MelanomaOcular Melanoma
Interventions
BIOLOGICAL

IOV-3001

IOV-3001 will be administered as a single dose by IV infusion, which will be administered in a hospital setting.

Trial Locations (2)

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

80218

RECRUITING

SCRI Oncology Partners- Denver, Denver

Sponsors
All Listed Sponsors
lead

Iovance Biotherapeutics, Inc.

INDUSTRY

NCT06940739 - A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel | Biotech Hunter | Biotech Hunter